---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Dosage"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Dosage. Topics: Intended commercial dose: one 20 mg immediate-release capsule, Phase 3 regimen: second capsule 4 hours or later for persisting or progressing non-laryngeal attacks, Phase 3 regimen: laryngeal attacks, Phase 3 regimen: washout of at least 72 hours between treated attacks, and 4 further topics. 8 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/dosage"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Dosage

<a id="heading-2.1.2.10.1"></a>

## 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

### Intended commercial dose: one 20 mg immediate-release capsule

> “RAPIDe-3, a pivotal global Phase 3 study evaluating deucrictibant immediate-release capsule (20 mg, which is the intended commercial dosage) for the on-demand treatment of HAE attacks in adults and adolescents (12 years and older)”

Source: [Pharvaris Form 6-K, second quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1830487/000095017025107316/phvs-ex99_1.htm)

<a id="topic-2.1.2.10.1-2"></a>

### Phase 3 regimen: second capsule 4 hours or later for persisting or progressing non-laryngeal attacks

> “If symptoms persisted or progressed, a second capsule of the same study drug was permitted 4 h or later after the first capsule, and conventional on-demand therapy as rescue medication was permitted 1 h or more after the second capsule for non-laryngeal attacks.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.10.1-3"></a>

### Phase 3 regimen: laryngeal attacks

> “For laryngeal attacks, a second capsule of study drug was not permitted, and rescue medication was allowed at any time.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.10.1-4"></a>

### Phase 3 regimen: washout of at least 72 hours between treated attacks

> “Following attack treatment with study drug (or after the second dose of study drug or conventional rescue medication, if used), a washout period of at least 72 h before treatment of the next attack with study drug was required to avoid potential carry-over effects.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.10.1-5"></a>

### Use of a second capsule in the phase 3 primary efficacy set of 88 participants with paired attacks

> “A second capsule was used for 15 (17%) and 19 (22%) of 88 deucrictibant-treated attacks and 59 (67%) and 61 (69%) of 88 placebo-treated attacks within 12 h and 24 h, respectively (appendix p 26).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

> “83.0% of deucrictibant-treated attacks were treated with a single capsule of deucrictibant and 93.2% did not require conventional treatment as rescue medication.”

Source: [Pharvaris EAACI 2026 press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/data-supporting-differentiated-profile-deucrictibant-hae)

<a id="topic-2.1.2.10.1-6"></a>

### Phase 2 dose range: 10, 20, and 30 mg as a single dose of three capsules

> “Capsules of deucrictibant and placebo were identical and each single dose consisted of a combination of three capsules of deucrictibant or placebo in a wallet.”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

> “a statistically significant and clinical meaningful reduction of the patient-reported symptoms of HAE was observed for the attacks treated with all doses of deucrictibant (10, 20, 30 mg) compared to placebo-treated attacks.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.2.10.1-7"></a>

### Open-label extension regimen: 20 mg in adults and adolescents (RAPIDe-2 part B)

> “Part A: double-blind deucrictibant 10 mg, 20 mg, or 30 mg.”
> “Part B, which also included adolescents: open-label deucrictibant 20 mg.”

Source: [Lesage et al. (2026a)](https://ir.pharvaris.com/static-files/832a8830-6fd1-41ac-b767-e1b348388853)

<a id="topic-2.1.2.10.1-8"></a>

### Combined use with the extended-release tablet during prophylaxis: modeled dosing scenarios

> “The evaluated scenarios (Table 1) included once daily deucrictibant XR tablet (40 mg, at steady state) combined with one deucrictibant IR capsule (20 mg), or two deucrictibant IR capsules taken 4 hours apart.”
> “Scenarios assumed that the first IR capsule was taken 6 hours (if only one capsule) or 2 hours (if two capsules) after the XR tablet, such that the peak plasma concentrations (Cmax) for the XR tablet and IR capsule(s) would be reached at the same time, providing a maximum peak of exposure in each scenario.”

Source: [Lesage et al. (2026b)](https://ir.pharvaris.com/static-files/67d704cc-422d-47b0-b130-9a6556fce46a)

> “The analysis demonstrated that combined use of a 40 mg deucrictibant XR tablet for prophylaxis and one or two deucrictibant IR 20 mg capsule(s), in the event of a breakthrough attack while on prophylaxis, is supported by evidence of adequate safety margins.”

Source: [Pharvaris EAACI 2026 press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/data-supporting-differentiated-profile-deucrictibant-hae)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
